Summary:
- This article discusses the results of a large real-world study in the United States that evaluated the effectiveness of the RSV (respiratory syncytial virus) vaccine BEYFORTUS® in reducing hospital and doctor visits for RSV disease in babies.
- The study found that BEYFORTUS® reduced hospital and doctor visits for RSV disease by 87% in babies, demonstrating its significant impact in protecting infants from this common and potentially serious respiratory illness.
- The findings highlight the importance of RSV vaccination in providing effective protection for vulnerable infants, helping to reduce the burden of RSV disease and associated healthcare utilization.